Last reviewed · How we verify

Prasterone (DHEA)

EndoCeutics Inc. · Phase 3 active Small molecule

Prasterone (DHEA) is a steroid hormone precursor that acts as a substrate for the synthesis of estrogen and androgen, restoring hormonal balance in postmenopausal women.

Prasterone (DHEA) is a steroid hormone precursor that acts as a substrate for the synthesis of estrogen and androgen, restoring hormonal balance in postmenopausal women. Used for Moderate to severe dyspareunia due to genitourinary syndrome of menopause (GSM) in postmenopausal women, Vaginal atrophy and related menopausal symptoms.

At a glance

Generic namePrasterone (DHEA)
Also known asIntrarosa
SponsorEndoCeutics Inc.
Drug classSteroid hormone precursor
TargetEstrogen receptor (ER), Androgen receptor (AR)
ModalitySmall molecule
Therapeutic areaWomen's Health / Gynecology
PhasePhase 3

Mechanism of action

Prasterone is an endogenous steroid hormone that serves as a precursor to both estrogen and testosterone. In postmenopausal women, systemic DHEA levels decline significantly, contributing to vaginal atrophy and related symptoms. By supplementing DHEA, the drug enables local and systemic conversion to active sex hormones, improving vaginal tissue health and alleviating symptoms of genitourinary syndrome of menopause (GSM).

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: